Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience / Desterro, J.; Mclornan, D. P.; Curto Garcia, N.; O'Sullivan, J.; Alimam, S.; Keohane, C.; Woodley, C.; Francis, Y.; Kordasti, S.; Radia, D. H.; Harrison, C. N.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - ELETTRONICO. - 186:4(2019), pp. 561-564. [10.1111/bjh.15968]